HIV

Colombia seeks to slash HIV drug costs by overriding ViiV’s patent

Colombia seeks to slash HIV drug costs by overriding ViiV’s patent

Anika Sharma

Colombia has taken a significant step in response to a pricing dispute with GSK’s ViiV Healthcare regarding the HIV medication ...

GSK aims to boost HIV sales to £7B with new drugs and launches

GSK aims to boost HIV sales to £7B with new drugs and launches

Anika Sharma

GSK is charting an optimistic course for its HIV business, buoyed by the success of its long-acting antiretroviral therapy, Cabenuva. ...

Injectable hydrogel delivers HIV drug for six weeks in mice study

Injectable hydrogel delivers HIV drug for six weeks in mice study

Anika Sharma

The landscape of HIV therapies has evolved significantly since the 1980s, when the FDA first approved the pioneering antiretroviral therapy ...

Injectable HIV Drug from ViiV Wins Over Patients in Switch Study

Patients prefer ViiV’s injectable HIV medication, according to a Switch research

SG Tylor

When ViiV Healthcare and Johnson & Johnson introduced their once-monthly injectable HIV treatment Cabenuva in 2021, they anticipated that patients ...

How Lenacapavir Can Change Life: New HIV Drug Shows Amazing Results

Twice-Yearly Lenacapavir Boosts HIV Patients’ Quality of Life

SG Tylor

Source – Gilead Gilead Sciences presented new data at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS ...

Biktarvy: The Breakthrough HIV Drug That Works for Everyone

Biktarvy Continues to Show Safety and Efficacy Across Diverse Populations Impacted by the Global HIV Epidemic: Updated Findings from IAS 2023

SG Tylor

Source – Gilead Gilead Sciences, has released the results of several studies further solidifying Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ...

How Gilead is Advancing Health Equity and HIV Innovation at IAS 2023

Gilead’s IAS 2023: Advancing Health Equity and HIV Pipeline Progress

SG Tylor

Source – Gilead On July 20, a leading force in HIV innovation, announced its significant participation in the 12th International ...

To increase treatment and adherence rates for children with HIV in low- and middle-income countries, Gilead collaborates with CHAI and Penta - Pharmtales

To increase treatment and adherence rates for children with HIV in low- and middle-income countries, Gilead collaborates with CHAI and Penta

SG Tylor

Source – Gilead Sciences Gilead Sciences is pleased to announce two collaborative initiatives. The first initiative aims to expedite the ...

Gilead and Teva were acquitted in a $3.6 billion trial involving alleged 'pay-for-delay' schemes - Pharmtales

Gilead and Teva were acquitted in a $3.6 billion trial involving alleged ‘pay-for-delay’ schemes

SG Tylor

Gilead Sciences and Teva have been exonerated by a California court jury in a lawsuit accusing them of colluding to ...